Medica 2010: Aipermon GmbH & Co. KG will present new ways of telemonitoring lung diseases

Press Release

At this year’s Medica Convention in Düsseldorf (17-20 November) Aipermon GmbH & Co. KG will present new ways of telemonitoring lung diseases

For the first time, the treatment of cystic fibrosis and COPD patients can now be continually monitored with telemonitoring devices.

At our stand in exhibition hall 15 C 39 visitors can also obtain more information on other Aipermon telemonitoring system approaches for diseases, e. g. cardiac insufficiency, diabetes, obesity, and high blood pressure.

Munich/Dusseldorf, 11. November 2010. Telemonitoring technology is employed increasingly for medical use. Flexible modules for telemonitoring systems, as developed by Aipermon, allow specialists to care for patients remotely in everyday life.

These systems can now also be used for diseases including lung conditions such as COPD (chronic obstructive pulmonary disease) and cystic fibrosis (inherited metabolic disorder also resulting in chronic inflammation of the lungs). Cooperations with the medical device manufacturers Vitalograph and PARI Pharma have opened up new approaches for this particular field. In 2010 these systems developed by Aipermon GmbH & Co. KG were extended to various other medical devices used for diagnosing and treating lung conditions. They are currently being tested in medical studies:

With regularly acquired data, collected over a long period of time, medical science hopes to better understand the factors affecting the disease and to find approaches for improving the intervention and medication.

For the monitoring of COPD, Aipermon has integrated the Vitalograph asma-1 peak flow meter into the telemetry platform. Data from the peak flow meter can now be transferred fully automatically to a mobile medical assistant (PDA with special software equipment) and from there to a medical care center. The Pneumology Department at Charité, Berlin uses this technology to prepare a study which allows for longterm monitoring of COPD patients in terms of lung function, physical activity (using the six-minutes walk test) and their own self-assessment. Correlated with climate data, scientists hope to find clues about the impact on the disease by atmospheric conditions (climate change).

Starting in 2011, the study is scheduled for two years and will include approx. 220 patients.
For the first time, the use of telemonitoring allows for continuous compliance monitoring in the treatment of cystic fibrosis and COPD patients. Aipermon technology, combined with eFlow® nebulizers by PARI Pharma, enables physicians to check whether the prescribed daily inhalation treatment for cystic fibrosis patients is implemented correctly and regularly.

The device fully automatically signals the date and time, duration and correct completion of each inhalation treatment. With the collection of this data, physicians using such a system, hope for a more successful treatment of cystic fibrosis patients, particularly children whose parents can receive counseling and support with remote monitoring.

Further telemonitoring system approaches for diseases such as cardiac insufficiency, diabetes, obesity, and high blood pressure will be demonstrated at the Aipermon stand in exhibition hall 15 / C 39.

About Aipermon
Aipermon GmbH & Co. KG is a manufacturer of telemedical systems based in Munich, Germany. The company offers complete telemonitoring systems for the remote transmission of medical results from home. The systems are employed in studies for the medical care of chronic patients, for movement intervention, movement prevention, and increasingly for medical intervention. In addition, Aipermon has developed AiperSunny activity sensors and AiperMotion 440TM, an Energy Balance Coach. The sensors are used for health promotion and weight loss programmes. In 2010 Aipermon won the FIBO Innovation Award in the “health promotion” category and the technology award as part of an initiative titled “Deutschland – Land des langen Lebens” (Germany – land of longevity).

Visit Aipermon at the Medica convention from 17-20 November 2010 in exhibition hall 15 /C 39.

For further information and image material please contact:

Press contact:
Aipermon GmbH & Co. KG
Zamdorfer Str. 100
81677 Munich-Germany
Phone: +49-(0)89-97890-0
E-Mail: info@aipermon.com
www.aipermon.com

Agency contact:
Huss-PR-Consult, Judith Huss
Lindenstrasse 4
D-82166 Munich-Gräfelfing
Phone: +49-(0)89- 649455-70
Fax: +49-(0)89- 649455-72
E-mail: judith.huss@hussprconsult.de

This release was published on openPR.